Characterization of KRAS-G12D ubiquitination and degradation by setidegrasib (ASP3082) and its combination potential in preclinical models (EORTC-NCI-AACR 2026) - Sep 11, 2026 - Abstract #227; PB-122; Pres time: Nov 19, 2026; Location: Exhibition Hall; "Abstract will be available as of 4 November (with consent of the author)"
Preclinical • Oncology • KRAS
|